liposarcoma (Cancer)
Information
- Disease name
- liposarcoma
- Disease ID
- DOID:3382
- Description
- "A connective tissue cancer that arises in fat cells in deep soft tissue retroperitoneum and the extremities." [url:http\://en.wikipedia.org/wiki/Liposarcoma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| ARID1B | 6 | 156,777,378 | 157,210,779 | 4 |
| TSPAN31 | 12 | 57,745,039 | 57,750,219 | 2 |
| CDK4 | 12 | 57,747,727 | 57,752,310 | 2 |
| APC | 5 | 112,737,885 | 112,846,239 | 2 |
| BRAF | 7 | 140,719,337 | 140,924,929 | 2 |
| BRCA1 | 17 | 43,044,295 | 43,125,483 | 2 |
| MDM2 | 12 | 68,808,177 | 68,845,544 | 2 |
| MIR6759 | 12 | 57,748,618 | 57,748,682 | 1 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT03526679 | Active, not recruiting | Phase 1/Phase 2 | Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma | July 12, 2018 | June 30, 2023 |
| NCT03899805 | Active, not recruiting | Phase 2 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | May 13, 2019 | August 1, 2025 |
| NCT03361436 | Active, not recruiting | Phase 1 | Eribulin and Radiation Therapy in Treating Patients With Retroperitoneal Liposarcoma That Can Be Removed by Surgery | March 19, 2018 | April 14, 2033 |
| NCT02923778 | Active, not recruiting | Phase 2 | Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery | December 31, 2019 | December 1, 2024 |
| NCT02978859 | Active, not recruiting | Phase 2 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | November 2016 | January 2023 |
| NCT01506596 | Completed | Phase 2 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | March 2012 | March 2016 |
| NCT01841047 | Completed | N/A | Assessment of Helical Tomotherapy Radiotherapy (54 Gy) Followed by Surgery in Retro-peritoneal Liposarcoma | January 20, 2009 | December 19, 2018 |
| NCT02048371 | Completed | Phase 2 | SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes | July 2014 | May 2022 |
| NCT02247544 | Completed | Phase 2 | Efficacy Study on Trabectedin in Retroperitoneal Leiomyosarcoma and Well Differentiated/Dedifferentiated Liposarcoma | March 2014 | March 12, 2019 |
| NCT02249949 | Completed | Phase 2 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | October 2014 | May 1, 2023 |
| NCT00093080 | Completed | Phase 2 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | October 2004 | November 2008 |
| NCT02343172 | Completed | Phase 1 | Study of Safety and Efficacy of HDM201 in Combination With LEE011 in Patients With Liposarcoma | March 13, 2015 | October 16, 2019 |
| NCT02584309 | Completed | Phase 2 | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma | February 22, 2016 | July 17, 2022 |
| NCT00060944 | Completed | Phase 2 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | May 2003 | May 2008 |
| NCT00132704 | Completed | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation | August 2004 | July 2014 | |
| NCT00356031 | Completed | Phase 2 | Bevacizumab and Radiation Therapy for Sarcomas | July 2006 | March 2010 |
| NCT00400569 | Completed | Phase 2 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | November 2006 | December 2011 |
| NCT01209598 | Completed | Phase 2 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | September 23, 2010 | October 25, 2016 |
| NCT01426633 | Completed | Phase 1 | Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas | November 2011 | December 2014 |
| NCT03303885 | Completed | The FGF/FGFR Signalling Pathway: | October 1, 2017 | March 29, 2019 | |
| NCT04715191 | Not yet recruiting | Phase 1 | Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | July 3, 2024 | July 3, 2041 |
| NCT06277154 | Not yet recruiting | Phase 2 | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma | February 2024 | February 2027 |
| NCT06414434 | Not yet recruiting | Phase 1 | BTX-A51 in Patients With Liposarcoma | November 2024 | June 1, 2027 |
| NCT06039046 | Not yet recruiting | Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients | October 2024 | October 2026 | |
| NCT06198296 | Not yet recruiting | Phase 1 | Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells | January 1, 2026 | February 1, 2043 |
| NCT04031677 | Recruiting | Phase 3 | Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | January 20, 2021 | April 21, 2028 |
| NCT02275286 | Recruiting | Phase 1/Phase 2 | Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients | November 2014 | June 2028 |
| NCT04028479 | Recruiting | The Registry of Oncology Outcomes Associated With Testing and Treatment | May 5, 2021 | October 1, 2031 | |
| NCT04224064 | Recruiting | N/A | Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas | August 26, 2020 | December 2025 |
| NCT04377932 | Recruiting | Phase 1 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Pediatric Solid Tumors | December 8, 2021 | February 1, 2040 |
| NCT04557449 | Recruiting | Phase 1/Phase 2 | Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors | September 23, 2020 | May 4, 2028 |
| NCT04785196 | Recruiting | Phase 1/Phase 2 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors | May 26, 2021 | January 2027 |
| NCT05094804 | Recruiting | Phase 1/Phase 2 | A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents | September 9, 2021 | August 15, 2024 |
| NCT05103631 | Recruiting | Phase 1 | Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors | June 17, 2021 | December 2039 |
| NCT05827614 | Recruiting | Phase 1 | Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications | March 24, 2023 | September 30, 2027 |
| NCT06239272 | Recruiting | Phase 1/Phase 2 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | March 27, 2024 | June 2037 |
| NCT06299163 | Recruiting | Phase 1 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | May 1, 2024 | December 31, 2027 |
| NCT02609984 | Terminated | Phase 2 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | April 29, 2015 | February 6, 2019 |
| NCT03959033 | Terminated | Patient Reported Outcome Measures (PROMs) With Trabectedin | November 29, 2016 | August 28, 2019 | |
| NCT05116683 | Terminated | Phase 2 | ATX-101 in Advanced Dedifferentiated Liposarcoma and Leiomyosarcoma | January 11, 2022 | October 27, 2022 |
| NCT02983539 | Unknown status | Detection of Circulating Tumor Cells in Patients With Sarcomas | October 2015 | June 2018 | |
| NCT03651375 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall | February 11, 2017 | March 2022 |
| NCT02571829 | Unknown status | Phase 2 | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | May 2016 | October 2017 |
| NCT05905341 | Withdrawn | Phase 1 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. | January 15, 2024 | April 13, 2028 |
| NCT03773510 | Withdrawn | Phase 3 | Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin | February 28, 2019 | October 1, 2025 |
| NCT04906876 | Withdrawn | Phase 2 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | September 2021 | July 2025 |
| NCT05116800 | Withdrawn | Phase 2 | Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma | March 1, 2022 | August 2030 |
| NCT03880123 | Withdrawn | Phase 1 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | November 2020 | November 24, 2020 |
- Disase is a (Disease Ontology)
- DOID:201
- Cross Reference ID (Disease Ontology)
- GARD:6913
- Cross Reference ID (Disease Ontology)
- ICDO:8850/3
- Cross Reference ID (Disease Ontology)
- MESH:D008080
- Cross Reference ID (Disease Ontology)
- NCI:C3194
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:254829001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0023827
- Exact Synonym (Disease Ontology)
- lipomatous cancer
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012034
- OrphaNumber from OrphaNet (Orphanet)
- 69078
- MeSH unique ID (MeSH (Medical Subject Headings))
- D008080